NCT07542782

Brief Summary

This study looks at how different treatment approaches affect survival in older people with pancreatic cancer that has not spread to other parts of the body. In particular, it focuses on patients aged 80 years and older who are still in relatively good general health and able to carry out normal daily activities. Pancreatic cancer is a serious disease, and surgery to remove the tumor is often the only treatment that offers a chance of longer survival. However, older patients are less likely to receive surgery, even if they are otherwise fit. Doctors may hesitate to recommend surgery mainly because of the patient's age, rather than their overall health condition. This study aims to better understand whether surgery can still be beneficial for these older patients. The study also examines the role of additional treatment after surgery, such as chemotherapy. In real-world medical practice, not all patients receive this follow-up treatment, especially older individuals who may have a slower recovery after surgery. This can make it difficult to understand whether such treatments truly improve survival. To answer these questions, the study uses data from a large cancer registry in Germany. It compares patients who had surgery with those who did not, and it also looks at patients who received additional treatment after surgery versus those who did not. Special methods are used to take into account that some patients may not have been able to receive further treatment because they did not recover well enough after surgery. The results of this study are intended to help doctors make better treatment decisions for older patients with pancreatic cancer, focusing more on their overall health and less on age alone.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,048

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2017

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2017

Completed
7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 12, 2024

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

April 15, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 21, 2026

Completed
Last Updated

April 21, 2026

Status Verified

April 1, 2026

Enrollment Period

7 years

First QC Date

April 15, 2026

Last Update Submit

April 15, 2026

Conditions

Keywords

Pancreatic resectionOctogenariansAdjuvant therapyPostoperative SurvivalReal-world dataECOG performance status

Outcome Measures

Primary Outcomes (1)

  • Overall Survival

    1 year overall survival after index surgery

Study Arms (2)

Patients younger than 80 years

Procedure: All types of surgical tumor resection procedures with curative intentProcedure: No surgical resection

Patients between 80 and 89 years

Procedure: All types of surgical tumor resection procedures with curative intentProcedure: No surgical resection

Interventions

Patients between 80 and 89 yearsPatients younger than 80 years
Patients between 80 and 89 yearsPatients younger than 80 years

Eligibility Criteria

Age18 Years - 89 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All residents of the Federal States Brandenburg and Berlin

You may qualify if:

  • Diagnosis of invasive pancreatic carcinoma
  • UICC stage I-III
  • No distant metastases (M0)
  • ECOG performance status 0-1
  • Diagnosis between Jan 1, 2017 and Dec 31, 2023
  • Residence in Berlin or Brandenburg

You may not qualify if:

  • Neuroendocrine tumors
  • Sarcomas

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical School Brandenburg

Brandenburg an der Havel, Brandenburg, 14770, Germany

Location

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

April 15, 2026

First Posted

April 21, 2026

Study Start

January 1, 2017

Primary Completion

December 31, 2023

Study Completion

October 12, 2024

Last Updated

April 21, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Individual participant data (IPD) cannot be shared. The data used in this study were obtained from a regional clinical cancer registry and are subject to strict data protection regulations. The dataset contains sensitive, potentially identifiable health information and is governed by legal restrictions that prohibit public data sharing.

Locations